Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Antiplatelet Drugs: Prostaglandin Synthesis, P2Y12 and Glycoprotein IIb/IIIa Inhibitors01:20

Antiplatelet Drugs: Prostaglandin Synthesis, P2Y12 and Glycoprotein IIb/IIIa Inhibitors

1.6K
Antiplatelet drugs emerge as frontline defenders against the insidious threat of thromboembolic diseases, where abnormal clots obstruct vital blood vessels. These drugs stand as bulwarks, inhibiting platelet aggregation and clot formation, thereby mitigating the risk of life-threatening conditions like myocardial infarction, coronary artery disease, and thrombotic strokes.
Prostaglandin synthesis inhibitors, exemplified by the widely known aspirin, wield their power by irreversibly acetylating...
1.6K
Peripheral Artery Disease III: Interprofessional Care01:27

Peripheral Artery Disease III: Interprofessional Care

655
Peripheral Artery Disease (PAD) is characterized by narrowed arteries that diminish blood flow to the extremities. Effective management of PAD requires an interprofessional approach involving various healthcare professionals. The critical aspects of interprofessional care for PAD patients focus on risk factor modification, drug therapy, exercise therapy, nutrition therapy, critical limb ischemia care, and interventional radiology and surgical procedures.The primary treatment goal for PAD...
655
Formation of the Platelet Plug01:22

Formation of the Platelet Plug

6.2K
The platelet phase, the second stage of hemostasis, commences around 15-20 seconds after an injury. It follows and overlaps with the vascular phase, during which blood vessels constrict to minimize blood loss.
As the injured blood vessel contracts, endothelial cells undergo contraction, revealing collagen fibers in the basement membrane and underlying connective tissue. Furthermore, the plasma membrane of endothelial cells becomes adhesive, preparing the site for platelet adhesion. Platelets...
6.2K
Anticoagulant Drugs: Low-Molecular-Weight Heparins01:30

Anticoagulant Drugs: Low-Molecular-Weight Heparins

2.6K
Hemostasis is a crucial process that prevents excessive blood loss from damaged blood vessels. It involves various mechanisms such as vasoconstriction, platelet adhesion and activation, and fibrin formation. The importance of each mechanism depends on the type of vessel injury. In contrast, thrombosis is the abnormal formation of a blood clot within the blood vessels, leading to potential complications if the clot obstructs blood flow. Thrombosis can be caused by increased coagulability of the...
2.6K
Atherosclerosis III: Management01:26

Atherosclerosis III: Management

741
Management of atherosclerosis involves an integrated strategy encompassing pharmacological treatment, surgical interventions, lifestyle changes, and nutrition therapy to address the multifactorial nature of the disease.Pharmacological TherapyA cornerstone of atherosclerosis management is the use of pharmacological agents. Statins, such as atorvastatin, are pivotal in inhibiting HMG-CoA reductase, an enzyme that catalyzes an initial step in cholesterol synthesis in the liver. This reduction in...
741
Venous Thrombosis III: Interprofessional Care01:29

Venous Thrombosis III: Interprofessional Care

482
Venous thrombosis requires effective prevention and treatment strategies to improve patient outcomes and reduce potential complications.Prevention StrategiesHealthcare providers must prioritize preventing venous thromboembolism (VTE) for all adult patients upon admission. Interventions depend on bleeding and thrombosis risk, medical history, current medications, diagnoses, planned procedures, and patient preferences. Patients on bed rest should change positions every two hours and, if not...
482

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

A historical review of the biological, semantic and clinical aspects of aspirin resistance.

Journal of thrombosis and haemostasis : JTH·2026
Same author

Inflammatory predictors of Post-COVID fatigue.

Brain, behavior, & immunity - health·2025
Same author

Systemic cytokines related to memory function 6-9 months and 12-15 months after SARS-CoV-2 infection.

Scientific reports·2024
Same author

Corrigendum to "Acute TNFα levels predict cognitive impairment 6-9 months after COVID-19 infection" [Psychoneuroendocrinology 153 (2023) 106104].

Psychoneuroendocrinology·2023
Same author

Acute TNFα levels predict cognitive impairment 6-9 months after COVID-19 infection.

Psychoneuroendocrinology·2023
Same author

Frequency of Abnormally Low Neuropsychological Scores in Post-COVID-19 Syndrome: the Geneva COVID-COG Cohort.

Archives of clinical neuropsychology : the official journal of the National Academy of Neuropsychologists·2022

Related Experiment Video

Updated: May 4, 2026

Ferric Chloride-induced Murine Thrombosis Models
10:37

Ferric Chloride-induced Murine Thrombosis Models

Published on: September 5, 2016

21.9K

Antiplatelet therapy: targeting the TxA2 pathway.

P Fontana1, A Zufferey, Y Daali

  • 1Division of Angiology and Haemostasis, Faculty of Medicine and University Hospitals of Geneva, 4, rue Gabrielle-Perret-Gentil, 1211, Geneva, Switzerland, pierre.fontana@hcuge.ch.

Journal of Cardiovascular Translational Research
|December 20, 2013
PubMed
Summary

The thromboxane A2 pathway amplifies platelet activation and contributes to atherosclerosis. New therapies targeting this pathway offer improved cardiovascular disease treatment beyond aspirin, especially in diabetes.

More Related Videos

A Method to Study the C924T Polymorphism of the Thromboxane A2 Receptor Gene
07:00

A Method to Study the C924T Polymorphism of the Thromboxane A2 Receptor Gene

Published on: April 1, 2019

11.7K
Turbidimetry on Human Washed Platelets: The Effect of the Pannexin1-inhibitor Brilliant Blue FCF on Collagen-induced Aggregation
09:13

Turbidimetry on Human Washed Platelets: The Effect of the Pannexin1-inhibitor Brilliant Blue FCF on Collagen-induced Aggregation

Published on: April 6, 2017

11.3K

Related Experiment Videos

Last Updated: May 4, 2026

Ferric Chloride-induced Murine Thrombosis Models
10:37

Ferric Chloride-induced Murine Thrombosis Models

Published on: September 5, 2016

21.9K
A Method to Study the C924T Polymorphism of the Thromboxane A2 Receptor Gene
07:00

A Method to Study the C924T Polymorphism of the Thromboxane A2 Receptor Gene

Published on: April 1, 2019

11.7K
Turbidimetry on Human Washed Platelets: The Effect of the Pannexin1-inhibitor Brilliant Blue FCF on Collagen-induced Aggregation
09:13

Turbidimetry on Human Washed Platelets: The Effect of the Pannexin1-inhibitor Brilliant Blue FCF on Collagen-induced Aggregation

Published on: April 6, 2017

11.3K

Area of Science:

  • Cardiovascular Science
  • Pharmacology
  • Thrombosis Research

Background:

  • The thromboxane (Tx) A2 pathway is crucial for platelet activation and atherosclerotic lesion development.
  • TxA2 acts via the thromboxane prostanoid (TP) receptor found on platelets, endothelial cells, macrophages, and monocytes.
  • This pathway is a significant target for cardiovascular disease treatment.

Purpose of the Study:

  • To review the role of the TxA2 pathway in cardiovascular disease.
  • To discuss the limitations of aspirin in inhibiting TxA2 synthesis.
  • To explore alternative therapeutic strategies for complete TxA2 pathway inhibition.

Main Methods:

  • Literature review of studies on the TxA2 pathway and its receptors.
  • Analysis of the mechanisms of action for aspirin and other antiplatelet agents.
  • Examination of novel drug development targeting TxA2 synthase and TP receptors.

Main Results:

  • Aspirin effectively inhibits platelet-derived TxA2 but its effects can be overcome by aspirin-insensitive agonists like isoprostanes.
  • Isoprostanes, prevalent in diabetes mellitus, represent a challenge to aspirin therapy.
  • Development of TxA2 synthase inhibitors and TP receptor antagonists aims for more comprehensive pathway blockade.

Conclusions:

  • The TxA2 pathway remains a critical therapeutic target in cardiovascular disease.
  • Limitations of aspirin highlight the need for alternative strategies, particularly for patients with conditions like diabetes.
  • Emerging drugs offer potential for superior inhibition of the TxA2 pathway, improving cardiovascular outcomes.